| Description |
1 online resource (x, 279 pages) : illustrations (some color) |
| Contents |
Intro; Foreword; Preface; Contents; 1: Infections: The Emergency of the New Millennium; 1.1 Introduction; 1.2 From Optimism to the Harsh Reality: The History of Infectious Diseases in the Past Century; 1.3 What Are Emerging Infectious Diseases (EIDs)?; 1.4 The New Millennium: Infectious Disease Threats; 1.5 The Healthcare-Associated Infections and Their Burden of Antimicrobial Resistance in the New Millennium; 1.6 Conclusions; References; 2: Gamma Camera Imaging of Infectious Diseases; 2.1 Clinically Validated and Commercially Available Radiopharmaceuticals |
|
2.1.1 111In-8-Hydroxyquinoline and 99mTc-Exametazime2.1.2 Gallium-67 Citrate; 2.1.3 99mTc-Besilesomab; 2.2 Experimental Radiopharmaceuticals; 2.2.1 99mTc-Ciprofloxacin; 2.2.2 99mTc-Ubiquicidin 29-41; 2.3 Future Perspectives and New Trends; References; 3: Radiopharmaceuticals for PET Imaging of Infection; 3.1 Introduction; 3.2 Clinically Validated/Tested and Commercially Available Radiopharmaceuticals; 3.2.1 [18F]FDG; 3.2.1.1 [18F]FDG and Different Microorganisms; 3.2.1.2 FDG Imaging of Some Site-Specific Infections Which Have Been Validated; Osteomyelitis; Spondylodiscitis |
|
Diabetic FootHip and Knee Prosthesis; Infected Vascular Graft; Infective Endocarditis; Cardiac Implantable Electronic Device Infections; 3.2.2 Labeled White Blood Cells; 3.2.3 [68Ga]Citrate; 3.2.4 Peptides; 3.2.5 Ubiquicidin (UBI) Fragments; 3.3 Experimental Radiopharmaceuticals; 3.3.1 Peptides; 3.3.1.1 Depsipeptide Derivative; 3.3.1.2 K-A9 Peptide; 3.3.2 Antibiotics; 3.3.2.1 Ciprofloxacin; 3.3.2.2 Trimethoprim; 3.3.2.3 Puromycin; 3.3.2.4 Rifampicin; 3.3.2.5 Isoniazid; 3.3.2.6 Pyrazinamide; 3.3.2.7 Fluconazole; 3.3.3 Antibody Labeling |
|
3.3.3.1 Antibodies Against Gram-Negative Bacteria3.3.3.2 Antibodies Against Gram-Positive Bacteria; 3.3.3.3 Antibody Against Simian Immunodeficiency Virus Envelope Protein; 3.3.3.4 Aspergillus Fumigatus-Specific Monoclonal Antibody JF5; 3.3.4 Imaging Targeted Molecules or Metabolism Specific to Microorganisms; 3.3.4.1 Siderophores; 3.3.4.2 Carbohydrate Metabolism; 3.3.5 Other Metabolites; 3.3.5.1 Fialuridine (FIAU); 3.3.5.2 Para-Aminobenzoic acid (PABA); 3.3.5.3 d-Methionine; 3.3.5.4 Prothrombin; 3.3.5.5 Transferrin |
|
3.3.6 Nonspecific Tracers Used in Infection to Discriminate Infection from Malignancy3.3.6.1 [18F]fluorothymidine ([18F]FLT); 3.4 Conclusion and Future Perspective; References; 4: Hybrid SPECT/CT and PET/CT Imaging in Infectious Diseases; 4.1 Introduction; 4.2 SPECT/CT Characteristics; 4.2.1 Basic Concepts; 4.2.1.1 Planar Imaging; 4.2.1.2 SPECT and SPECT/CT; 4.2.2 Improved Anatomical Location; 4.2.3 Motion Correction and Iterative Reconstructions; 4.2.4 Attenuation and Scatter Correction; 4.2.5 Disadvantages; 4.2.6 Partial Volume Effects |
| Summary |
This book is designed as a reference manual that is exceptional in systematically discussing every aspect of nuclear medicine imaging of infections, with careful explanation of the most up-to-date concepts and recent guidelines on diagnostic flowcharts as shared between the EANM, ESR, ESNR, ESCMID, ESC, EACVI, ECCO, ESGAR and EBJIS. It is truly comprehensive, describing all methods, all acquisition parameters, and all interpretation criteria in all infectious diseases. The early chapters discuss currently available radiopharmaceuticals and nuclear medicine imaging technologies, including the hybrid modalities SPECT/CT, PET/CT, and PET/MRI. The remainder of the book is devoted to the nuclear medicine imaging of infections at different body sites as well as fever of unknown origin, fungal infections, and tuberculosis and AIDS-associated infections. Infections represent a real emergency globally, and early diagnosis and treatment follow-up will continue to pose huge challenges. In this context, Nuclear Medicine in Infectious Diseases will be a superb asset for nuclear medicine and infectious disease specialists and other clinicians everywhere |
| Notes |
4.3 Spect Quantitation and Its Relevance for Imaging Infections |
|
Print version record |
| Subject |
Nuclear medicine.
|
|
Communicable diseases -- Imaging
|
|
Communicable Diseases -- therapy
|
|
Communicable Diseases -- diagnosis
|
|
Nuclear Medicine -- methods
|
|
Radiopharmaceuticals -- therapeutic use
|
|
Positron Emission Tomography Computed Tomography
|
|
Fluorodeoxyglucose F18 -- therapeutic use
|
|
Nuclear Medicine
|
|
Nuclear medicine
|
| Form |
Electronic book
|
| Author |
Signore, A. (Alberto), 1959-
|
|
Glaudemans, Andor W. J. M. (Andor Waltherus Johannes Maria), 1976-
|
| ISBN |
3030254941 |
|
9783030254940 |
|
